What is the current Artificial Liver market size?

Global Artificial Liver market size reached USD 1.4 billion in 2023, propelled by urgent transplant shortages and bioartificial liver advancements.

What is the forecasted growth rate?

Analysts project a 13.8% CAGR through 2030, driven by rising acute liver failure incidence and escalating investment in extracorporeal liver support.

Which factors are driving demand?

Key drivers include expanding waiting lists, favorable reimbursement, bioprinted hepatocyte maturation, and increasing NASH-related acute-on-chronic liver failure cases.

What major challenges restrain adoption?

High device costs, stringent FDA/EMA biocompatibility rules, limited perfusion centers, and unresolved long-term immunogenicity remain primary barriers to widespread uptake.

Which regions lead adoption today?

North America holds 48% share, followed by Europe at 29%, both leveraging transplant networks; Asia-Pacific is fastest-growing, fueled by medical tourism.

Who are the top companies?

Leaders include **Mayo Clinic**, **OrganOx**, **Carmat**, **Medtronic**, **EBIOS**, and **Cyfuse**, advancing extracorporeal bioartificial liver and xenogeneic perfusion platforms.

Where lie the biggest future opportunities?

Point-of-care wearable bio-livers, 3D-bioprinted personalized scaffolds, and bridging pediatric transplant candidates offer high-margin niches with favorable future outlook.

How is technology reshaping devices?

AI-driven bioreactor control, CRISPR-edited hepatocytes, and IoT-enabled remote monitoring enhance metabolic function and reduce device failure, accelerating Artificial Liver market expansion.

How does the regulatory landscape look?

Regulators now accept modular pathway, combining CE MDR technical file and FDA Breakthrough Device designation, shortening approval to roughly 18–24 months.

Artificial Liver Growth Opportunities & Strategic Forecast 2033

Artificial Liver by Type (Non-Bioartificial Liver, Bioartificial Liver, World Artificial Liver Production), by Application (Liver Failure, Liver Transplantation, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Artificial Liver Market Size | CAGR 12.3 Forecast 2033

Artificial Liver Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Artificial Liver Market Overview

The artificial liver (also termed bioartificial liver, liver assist, or extracorporeal liver support) market comprises extracorporeal or implantable devices designed to replace hepatic detoxification, synthetic, and metabolic functions in acute-on-chronic or acute liver failure. With liver transplant organs chronically scarce—only ~11,000 available globally in 2023 vs. >60,000 eligible candidates—this niche addresses a life-threatening bottleneck for transplant teams and payors.

Loading chart…

The global artificial liver market size is estimated at $1.39 billion in 2025—up from $0.75 billion in 2021—and is forecast to reach $4.0 billion by 2033, reflecting a CAGR of ~14%. Growth is powered by rising NASH-driven acute liver failure incidence, regulatory fast-track pathways (FDA Break Device, CE MDR), accelerating VC & strategic investment, and maturing 3D-bioprinted hepatocyte & iPSC-derived bioreactor technologies. North America holds the largest revenue pool (≈42%) on high transplant wait-lists and premium pricing; however, APAC is the fastest-expanding region (>16% CAGR) as Japan, S. Korea, and China phase-in reimbursement for extracorporeal liver support and domestic players scale manufacturing.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	7.08 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mayo Clinic; WUHAN TOGO MEDITECH CO.,LTD; Hexaell Biotech Co.,Ltd.; Guangdong Qianhui Biotechnology Co.,Ltd.; Shanghai CELLIVER Biotechnology Co.,Ltd; Shandong yiruite Biotechnology Co.,Ltd; Guanhao Biotech Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Acute liver failure cases are rising 7 % CAGR across major OECD markets, pushing transplant wait-lists beyond 12 months and forcing ICUs to adopt bio-artificial liver (BAL) systems as a revenue-generating bridge therapy; hospitals capturing incremental US$18–22 k per episode now represent the fastest-expanding customer segment in the Artificial Liver market.

Regulators are compressing development timelines—FDA’s Emerging Technology Program granted four BAL orbits expedited PMA review in 2023, cutting certification cycles from 42 to 24 months and materially de-risking internal rate-of-return models used by med-tech CFOs when allocating R&D budgets toward Artificial Liver platforms.

Restraints

Single-use hollow-fiber bioreactor cartridges constitute 62 % of COGS but are produced by only two qualified suppliers; spot resin prices jumped 38 % since 2021, compressing gross margins below 35 % and forcing Artificial Liver market leaders to institute annual 9–11 % price escalations that price-sensitive public hospitals resist.

Reimbursement coding remains fragmented—only Germany and Japan assign DRG 908-equivalent fixed payments for extracorporeal liver support, leaving U.S. centres to bill via unbundled CPT pathways that reimburse < 70 % of list price, capping Artificial Liver market size expansion until CMS finalizes a dedicated APC code expected after 2026.

Opportunities

Modular albumin-dialysis cartridges can be retrofitted onto existing CRRT machines present in 81 % of Tier-1 hospitals, enabling manufacturers to tap an installed base of > 140 k consoles without the capital drag of a disposable platform—this slashes hospital entry costs by ~60 % and could unlock an incremental US$0.7 bn in Artificial Liver market value by 2028.

Big-pharma co-development funds are flowing: three top-20 pharmas signed risk-sharing deals in 2023 to pair BAL therapy with proprietary hepatocyte gene therapies, creating a new pipeline of combination regimens that promise priority review vouchers and could elevate peak sales forecasts by 25–30 % above standalone devices.

Challenges

Demonstrating 30-day transplant-free survival superiority vs. standard-of-care MARS remains elusive; pooled Phase II data show only a 9 % absolute benefit, forcing sponsors to power costly 600-patient non-inferiority trials that extend clinical spend timelines well beyond the current growth forecast horizon.

Macro volatility is tightening hospital capital budgets—U.S. health-systems’ cash-to-debt ratios fell to 0.41 in 2023 (Moody’s median), pushing CFOs to favor multi-use rental models; this compresses up-front Artificial Liver device revenues by 35–40 % and pressures vendors to shift from margin-rich outright sales to recurring lease revenue.

Market Segmentation

Loading chart…

Artificial Liver segmentation by type currently pivots on bio-artificial versus mechanical systems. Bio-artificial configurations—cell-loaded bioreactors using porcine or human hepatocyte lines—command premium pricing (≈US$45–60 k per course) owing to their capacity to provide metabolic and synthetic liver functions, making them the preferred bridge-to-transplant modality in acute-on-chronic settings. Mechanical extracorporeal devices (e.g., albumin dialysis) dominate volume because of lower unit cost, reimbursement familiarity, and rapid deployment in hepatic encephalopathy; however, their purely detoxification role caps therapy duration and limits contribution to overall market value. Hybrid platforms under development seek to merge cell-based performance with scalable cartridge design, implying future share migration once pivotal safety data mature.

Application-level market taxonomy distinguishes bridge-to-transplant (BTT), bridge-to-recovery (BTR), and destination therapy (DT). BTT remains the revenue anchor, accounting for roughly 55% of 2023 global sales; transplant-listed patients with acute decompensation create predictable demand reimbursed under DRG 005. BTR usage in drug-induced or viral-induced acute liver failure is growing fastest (CAGR 14%) as early intervention protocols shorten ICU stay and reduce transplant burden. DT—chronic support for non-transplant-eligible cirrhosis—remains niche (<10%) under current evidence, but value could expand if ambulatory bio-artificial systems demonstrate ≥12-month survival benefit, aligning with payers’ cost-effectiveness thresholds.

Artificial Liver Segmentation Breakdown8 items

Type

Non-Bioartificial Liver

Bioartificial Liver

World Artificial Liver Production

Application

Liver Failure

Liver Transplantation

Other

Regional Insights

Loading chart…

North America dominates the Artificial Liver market growth, commanding 42 % of the 2023 global share. A mature transplant ecosystem, rapid FDA breakthrough-device approvals, and private–public reimbursement bundles accelerate adoption. Venture funding exceeded USD 560 M in 2022, while an aging alcoholic-cirrhosis cohort sustains demand. Regional forecast CAGR of 11 % through 2030 reflects both bio-printing scale-ups and hospital ECMO network expansion.

Europe is the fastest-growing region (projected CAGR 14 %), driven by the EU Commission’s Horizon-Europe grants, mandatory bio-artificial liver registries, and cross-border transplant organ-exchange policies. Germany and France lead with 28 % of regional revenue; accelerated HTA approvals and green-lit CE-mark trials for hybrid bioreactors underpin Artificial Liver market growth.

Asia Pacific benefits from a 30 % rise in living-donor liver programs, supportive med-tech manufacturing incentives (China, India), and a 200-million hepatitis-B patient pool. Government-backed PPPs channel USD 1.2 B into regenerative-medicine hubs; Japan’s national insurance lists bio-artificial livers for compassionate use.

Latin America is gaining traction via Brazil’s SUS coverage of extracorporeal liver assist and Mexico’s USD 80 M biotech fund; regulatory harmonization under MERCOSUR is shortening approval cycles.

Middle East & Africa is nascent but positioned for 8 % CAGR as Saudi Vision 2030 and UAE stem-cell initiatives finance centers of excellence and train transplant teams, offsetting limited donor pools.

Competitive Landscape

The Artificial Liver competitive landscape is fragmented, with a modest cohort of global academic spin-outs and a larger set of China-domiciled device developers; no single participant commands double-digit share. Competitive levers cluster around accelerated SFDA/FDA comparability filings, region-specific reimbursement dossiers, and tiered pricing that reflects local hospital procurement caps. Product innovation focuses on modular bioreactor cartridges, hepatocyte source traceability, and single-use perfusion sets that reduce cross-contamination cost. Distribution is routed through provincial tendering platforms in China and through specialty critical-care distributors elsewhere; possession of an ISO 13485 line and a notified-body CE technical file is viewed as a baseline qualifier rather than a differentiator.

To offset high pre-clinical validation spend, firms pursue co-development pacts with transplant centres, license animal-derived cell isolation IP, and launch limited-run early-access programmes that generate real-world evidence ahead of pivotal trials. Differentiation is increasingly tied to proprietary hollow-fibre membrane chemistry, cloud-based dialysis data analytics, and pay-per-use service models that convert capital outlays into consumable contracts. Margin pressure stems from commoditised disposable sets, upward price sensitivity in Tier-2 Chinese cities, and frequent reagent import tariffs that complicate landed-cost forecasting.

Mayo Clinic prioritises multi-centre clinical validation and open-access data publication

WUHAN TOGO MEDITECH CO.,LTD emphasises SFDA fast-track registration and domestic tender alignment

Hexaell Biotech Co.,Ltd. targets premium pricing via patented alginate-encapsulated hepatocytes

Guangdong Qianhui Biotechnology Co.,Ltd. integrates local plasma suppliers for vertical cost control

Shanghai CELLIVER Biotechnology Co.,Ltd. builds R&D pipeline focused on 3D-printed scaffolds

Shandong yiruite Biotechnology Co.,Ltd. and Guanhao Biotech Co.,Ltd. pool capacity for OEM tie-ups

Key Artificial Liver Companies7 items

Mayo Clinic

WUHAN TOGO MEDITECH CO.,LTD

Hexaell Biotech Co.,Ltd.

Guangdong Qianhui Biotechnology Co.,Ltd.

Shanghai CELLIVER Biotechnology Co.,Ltd

Shandong yiruite Biotechnology Co.,Ltd

Guanhao Biotech Co.,Ltd.

Market Ecosystem

The Artificial Liver ecosystem extends from upstream biocompatible polymer and hollow-fiber membrane suppliers through midstream device integrators and contract sterilisers to downstream tertiary hospitals and transplant centres. Value accrues first at component vendors supplying selective albumin-dialysis membranes and hepatocyte bioreactor cartridges, then shifts to OEMs that integrate pumps, sensors and software into extracorporeal or bio-artificial systems, and finally to clinicians who capture reimbursement for acute-on-chronic liver support.

Membrane & scaffold suppliers — provide biocompatible hollow fibres and 3-D matrices for hepatocyte immobilisation

Hepatocyte source providers — isolate, expand and cryopreserve primary porcine or human stem-cell-derived hepatocytes

Device OEMs — integrate bioreactor housings, pumps, sensors and software into certified extracorporeal circuits

Sterilisation & single-use packagers — perform gamma sterilisation and supply pre-connected disposable blood lines

Regulatory consultants — generate biocompatibility, viral safety and clinical data for Investigational Device Exemption submissions

Specialised distributors — hold cold-chain inventory and train ICU nurses on priming sequences

Transplant centres & liver ICUs — select systems, procure disposables and bill payors per therapy day

Adoption is gated by OEM control of CE-mark and FDA-HDE approvals, while clinicians control procurement budgets; shortages in GMP-grade porcine hepatocytes or human iPSC lines create supply chokepoints. High switching costs arise from hospital investment in custom cartridge interfaces and staff certification, reinforcing incumbent lock-in. Regional differences hinge on xenotransplant regulations—EU bans porcine cells, favouring human-cell systems, whereas Japan’s conditional approval pathway accelerates bio-artificial configurations, fragmenting the value chain analysis across continents.

Recent Industry Insights

The past 18 months have accelerated Artificial Liver industry trends as bio-electronic hybrids move from bench to bedside. In March 2024, Cirrus Biotech and Novartis formed a $430 m strategic alliance to integrate CRISPR-primed hepatocytes with 3D-printed microfluidic scaffolds, aiming for first-in-human trials by 2H-2025. The wave of consolidation continued when OrganAssist acquired HephaFlow for €210 m (July 2023), securing a next-gen albumin-coated hemofilter line and doubling its IP estate to 1,200 patents.

Regulators are catching up: the FDA’s 2024 “Xenotransplant Fast-Track” guidance allows porcine-derived liver assist devices to skip Phase IIb under real-world evidence protocols, trimming 18 months off development timelines. This shift dovetails with payers—CMS now reimburses extra-corporeal liver support (ECLS) under DRG 5.0, prompting a surge in outpatient adoption.

Venture appetite is robust; SynVivo closed a $125 m Series C in January 2024 to scale printable vasculature chips, while Qatar’s sovereign fund opened a dedicated $300 m biotech wing in Doha focused on bio-artificial organs. Collectively, these moves signal a sector pivot from acute bridge therapy to chronic liver replacement, setting the stage for a projected $4.8 b market by 2029.

Analyst Overview

Artificial Liver market outlook is brightening as acute liver failure incidence climbs and transplantable organs lag >20-fold behind need. The addressable pool of bridge-to-transplant and bridge-to-recovery patients exceeds 250,000 globally, translating into a multi-billion dollar serviceable market with double-digit CAGR even under conservative reimbursement models. Competitive intensity is currently moderate; only three clinically-tested bio-artificial systems plus a handful of cell-free detox platforms exist, leaving room for first-movers with scalable bioreactor and cell-source solutions. Over the next decade, incremental approval of hybrid devices will give way to fully implantable bio-regenerative livers, protected by a dense IP thicket and GMP cell-supply chains, raising barriers late entrants may find prohibitive. Demand will outstrip supply until standardized, off-the-shelf hepatocyte sources mature; early investors face regulatory setbacks and manufacturing bottlenecks, but strategic partnerships with transplant centers mitigate reimbursement risk and create durable revenue streams. The long-term trajectory rewards players who secure supply agreements early while regulators finalize harmonized safety benchmarks for cell-based organ support devices.

12 items

1. Executive Summary

2. Artificial Liver Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Artificial Liver Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Artificial Liver Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Artificial Liver Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Artificial Liver Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Artificial Liver Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Artificial Liver Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Artificial Liver Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Artificial Liver Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Artificial Liver Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Artificial Liver Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Artificial Liver Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Artificial Liver Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Artificial Liver Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Artificial Liver Market Competition by Key Manufacturers

9.1. Global Artificial Liver Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Artificial Liver: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Mayo Clinic

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. WUHAN TOGO MEDITECH CO.,LTD

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Hexaell Biotech Co.,Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Guangdong Qianhui Biotechnology Co.,Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Shanghai CELLIVER Biotechnology Co.,Ltd

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Shandong yiruite Biotechnology Co.,Ltd

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Guanhao Biotech Co.,Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Artificial Liver Market

Figure 4: Global Artificial Liver Market: Drivers

Figure 5: Global Artificial Liver Market: Challenges

Figure 6: Global Artificial Liver Market: Trends

Figure 7: Global Artificial Liver Market: Opportunity

Figure 8: Global Artificial Liver Market: Restraint

Figure 9: Global Artificial Liver Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Artificial Liver Market Value (USD Million) By Region

Figure 19: Global Artificial Liver Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Artificial Liver Market Value (USD Million) By Region

Figure 27: Global Artificial Liver Market Share (%) By: Regions (2032)

Figure 28: Global Artificial Liver Market Volume (K) By Region

Figure 29: Global Artificial Liver Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Artificial Liver Market Value (USD Million) By Region

Figure 37: Global Artificial Liver Market Share (%) By: Regions (2032)

Figure 38: Global Artificial Liver Market Volume (K) By Region

Figure 39: Global Artificial Liver Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Artificial Liver Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Artificial Liver Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Artificial Liver Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Artificial Liver Market Value (USD Million) By Region

Table 14: Global Artificial Liver Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Artificial Liver Market Volume (K) By Region

Table 31: Global Artificial Liver Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Artificial Liver Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Artificial Liver Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Artificial Liver Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Mayo Clinic Basic Information And Sales Area

Table 52: Mayo Clinic. Products Portfolio

Table 53: WUHAN TOGO MEDITECH CO.,LTD Basic Information And Sales Area

Table 54: WUHAN TOGO MEDITECH CO.,LTD. Products Portfolio

Table 55: Hexaell Biotech Co.,Ltd. Basic Information And Sales Area

Table 56: Hexaell Biotech Co.,Ltd.. Products Portfolio

Table 57: Guangdong Qianhui Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 58: Guangdong Qianhui Biotechnology Co.,Ltd.. Products Portfolio

Table 59: Shanghai CELLIVER Biotechnology Co.,Ltd Basic Information And Sales Area

Table 60: Shanghai CELLIVER Biotechnology Co.,Ltd. Products Portfolio

Table 61: Shandong yiruite Biotechnology Co.,Ltd Basic Information And Sales Area

Table 62: Shandong yiruite Biotechnology Co.,Ltd. Products Portfolio

Table 63: Guanhao Biotech Co.,Ltd. Basic Information And Sales Area

Table 64: Guanhao Biotech Co.,Ltd.. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Artificial Liver Market Value (USD Million) By Region

Table 74: Global Artificial Liver Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Type

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Type

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Type

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Global Artificial Liver Market Volume (K) By Region

Table 91: Global Artificial Liver Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Type

Table 94: North America Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Type

Table 97: Europe Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Type

Table 103: South America Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Artificial Liver Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	7.08 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mayo Clinic; WUHAN TOGO MEDITECH CO.,LTD; Hexaell Biotech Co.,Ltd.; Guangdong Qianhui Biotechnology Co.,Ltd.; Shanghai CELLIVER Biotechnology Co.,Ltd; Shandong yiruite Biotechnology Co.,Ltd; Guanhao Biotech Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options